Synopsis
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Erycette
2. Erymax
3. Erythromycin A
4. Erythromycin C
5. Erythromycin Lactate
6. Erythromycin Phosphate
7. Ilotycin
8. Lactate, Erythromycin
9. Phosphate, Erythromycin
10. T Stat
11. T-stat
12. Tstat
1. 114-07-8
2. Erythromycin A
3. E-mycin
4. Ilotycin
5. Abomacetin
6. Erymax
7. Erythromycinum
8. Emgel
9. Erycette
10. Robimycin
11. Erythro-statin
12. E-glades
13. Erythrocin
14. Ery-tab
15. E-base
16. Eritromicina
17. Erythromycine
18. Erygel
19. Sansac
20. Erythra-derm
21. Akne-mycin
22. Eryc
23. Erythromycin Base
24. T-stat
25. Eryacne
26. R-p Mycin
27. E-solve 2
28. Torlamicina
29. Eryderm
30. C-solve-2
31. Pantomicina
32. A/t/s
33. Erythro
34. Erythroguent
35. Eritrocina
36. Propiocine
37. Stiemycin
38. Ermycin
39. Erycen
40. Aknin
41. Theramycin Z
42. Erythromycin-a
43. Ak-mycin
44. Erythromast 36
45. (-)-erythromycin
46. Benzamycin
47. Emycin
48. Erytab
49. Inderm
50. Retcin
51. Chembl532
52. Dumotrycin
53. Mephamycin
54. Chebi:42355
55. Wemid
56. J01fa01
57. Eryc Sprinkles
58. Mfcd00084654
59. Nsc-55929
60. 63937kv33d
61. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-(((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
62. Erythromycin C-13
63. Endoeritrin
64. Eritomicina
65. Erythroderm
66. Erytrociclin
67. Pharyngocin
68. Proterytrin
69. Acneryne
70. Acnesol
71. Aknemycin
72. Derimer
73. Deripil
74. Erisone
75. Eryacnen
76. Erydermer
77. Eryhexal
78. Erysafe
79. Iloticina
80. Latotryd
81. Lederpax
82. Mercina
83. Oftamolets
84. Pantoderm
85. Pantodrin
86. Primacine
87. Romycin
88. Stiemicyn
89. Tiprocin
90. Emuvin
91. Erecin
92. Erymed
93. Erytop
94. Nci-c55674
95. Austrias
96. Eros
97. Ery-maxin
98. Erythro-teva
99. Sans-acne
100. Dsstox_cid_2991
101. Erimycin-t
102. Ery-diolan
103. Inderm Gel
104. Del-mycin
105. Aknederm Ery Gel
106. Udima Ery Gel
107. Eryc 125
108. Dsstox_rid_76820
109. Dsstox_gsid_22991
110. Emu-ve
111. 8hph7nd0ln
112. Skid Gel E
113. (3r*,4s*,5s*,6r*,7r*,9r*,11r*,12r*,13s*,14r*)-4-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione
114. Akne Cordes Losung
115. Ery
116. Ilosone (estolate)
117. Ilotycin T.s.
118. E-mycin (base)
119. Ery-tab (base)
120. Emu-v
121. Ery-b
122. E-base (base)
123. Eryc (base)
124. N-methylerythromycin A
125. Pce Dispertab (base)
126. Eryc-125
127. Eryc-250
128. Eritromicina [inn-spanish]
129. Erythromycine [inn-french]
130. Erythromycinum [inn-latin]
131. Erythromycin, Labeled With Carbon-13
132. Oftalmolosa Cusi Eritromicina
133. Staticin (tn)
134. Akne-mycin (tn)
135. Erygel (tn)
136. Eryc (tn)
137. T-stat (tn)
138. Pce (tn)
139. Sr-05000001618
140. Sentry Aq Mardel Maracyn
141. 9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
142. Erthromycin
143. Erythromycines
144. Nsc55929
145. Ccris 9078
146. Unii-63937kv33d
147. Hsdb 3074
148. Ncgc00094670-01
149. Erythromycin [usp:inn:ban:jan]
150. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,
151. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
152. Cas-114-07-8
153. Prestwick_205
154. Einecs 204-040-1
155. Nsc 55929
156. 215031-94-0
157. Spectrum_000115
158. Spectrum_000659
159. Ai3-50138
160. Em-a
161. Prestwick3_000151
162. Spectrum2_000759
163. Spectrum2_001263
164. Spectrum4_000538
165. Spectrum5_001596
166. Unii-8hph7nd0ln
167. Erythromycin [mi]
168. E0751
169. Erythromycin [inn]
170. Erythromycin [jan]
171. Pce (erythromycin)
172. Ec 204-040-1
173. Erythromycin [hsdb]
174. Schembl2601
175. Erythromycin [vandf]
176. Bspbio_000282
177. Bspbio_002480
178. Erythromycin [mart.]
179. Erythromycin Standard Solution
180. Kbiogr_001175
181. Kbioss_000555
182. Kbioss_001139
183. 82343-12-2
184. Mls001066618
185. Bidd:gt0017
186. Divk1c_000294
187. Divk1c_000397
188. Divk1c_000702
189. Erythromycin [usp-rs]
190. Erythromycin [who-dd]
191. Erythromycin [who-ip]
192. Spectrum1500280
193. Spbio_000778
194. Spbio_001226
195. Bpbio1_000312
196. Gtpl1456
197. Dtxsid4022991
198. Erythromycin (jp17/usp/inn)
199. Hms500o16
200. Kbio1_000294
201. Kbio1_000397
202. Kbio1_000702
203. Kbio2_000555
204. Kbio2_001139
205. Kbio2_003123
206. Kbio2_003707
207. Kbio2_005691
208. Kbio2_006275
209. Erythromycin [green Book]
210. Erythromycin (mixture Of A,b,c)
211. Ninds_000294
212. Ninds_000397
213. Ninds_000702
214. Erythromycin [orange Book]
215. Hms1920m04
216. Hms2091d05
217. Hms2095o04
218. Hms3712o04
219. Pharmakon1600-01500280
220. Erythromycin [ep Monograph]
221. Act03320
222. Hy-b0220
223. Rkl10096
224. Erythromycin [usp Monograph]
225. Tox21_111311
226. Tox21_111869
227. Tox21_300515
228. Bdbm50344942
229. Ccg-38992
230. Lmpk04000006
231. Nsc756759
232. Zinc85534336
233. Erythromycinum [who-ip Latin]
234. Akos015895249
235. Db00199
236. Nsc-756759
237. Benzamycin Component Erythromycin
238. Idi1_000294
239. Idi1_000397
240. Idi1_000702
241. Smp1_000119
242. Ncgc00179619-01
243. Ncgc00179619-02
244. Ncgc00179619-03
245. Ncgc00254234-01
246. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
247. Ac-12744
248. Ac-12901
249. Smr000544946
250. Erythromycin Component Of Benzamycin
251. Erythromycin, Potency: >=850 Mug Per Mg
252. Erythromycin, Tested According To Ph.eur.
253. Sbi-0051368.p003
254. Erythromycin, N-demethyl-n-(methyl-11c)-
255. Erythromycin 1000 Microg/ml In Acetonitrile
256. Erythromycin, Meets Usp Testing Specifications
257. C01912
258. D00140
259. E-3250
260. Erythromycin, Plant Cell Culture Tested, ~98%
261. Ab00051981_09
262. Ab00051981_10
263. Erythromycin Standard Solution, 1 Mg/ml In H2o
264. Erythromycin, Biotechnology Performance Certified
265. 114e078
266. Erythromycin Estolate Impurity, Free Erythromycin-
267. Q213511
268. Sr-01000799155
269. Erythromycin, Antibiotic For Culture Media Use Only
270. Erythromycin, Bioreagent, Suitable For Cell Culture
271. Sr-01000799155-2
272. Sr-05000001618-1
273. Sr-05000001618-2
274. Brd-k63550407-001-13-5
275. Brd-k63550407-028-03-9
276. Erythromycin (mixture Of A,b,c) 100 Microg/ml In Acetonitrile
277. Erythromycin A, British Pharmacopoeia (bp) Reference Standard
278. Erythromycin A, European Pharmacopoeia (ep) Reference Standard
279. Erythromycin, United States Pharmacopeia (usp) Reference Standard
280. Erythromycin Estolate Impurity, Free Erythromycin [ep Impurity]
281. Erythromycin Estolate Impurity, Free Erythromycin- [usp Impurity]
282. Erythromycin, For Microbiological Assay, European Pharmacopoeia (ep) Reference Standard
283. Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
284. (3r*,4s*,5s*,6r*,7r*,9r*,11r*,12r*,13s*,14r*)-4-[(2,6-dideoxy-3-c-methyl-3-o-methyl-.alpha.-l-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-
285. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-4-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
286. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
287. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
288. (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred Name)
289. [3r-(3r*,4s*,5s*,6r*,7r*,9r*,11r*,12r*,13s*,14r*)]-4-[(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione
| Molecular Weight | 733.9 g/mol |
|---|---|
| Molecular Formula | C37H67NO13 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 7 |
| Exact Mass | 733.46124119 g/mol |
| Monoisotopic Mass | 733.46124119 g/mol |
| Topological Polar Surface Area | 194 Ų |
| Heavy Atom Count | 51 |
| Formal Charge | 0 |
| Complexity | 1180 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 18 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 24 | |
|---|---|
| Drug Name | Akne-mycin |
| Active Ingredient | Erythromycin |
| Dosage Form | Ointment |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Dow Pharm |
| 2 of 24 | |
|---|---|
| Drug Name | Benzamycin |
| Active Ingredient | Benzoyl peroxide; erythromycin |
| Dosage Form | Gel |
| Route | Topical |
| Strength | 5%; 3% |
| Market Status | Prescription |
| Company | Valeant Intl |
| 3 of 24 | |
|---|---|
| Drug Name | Benzamycin pak |
| Drug Label | ERYC capsules contain enteric-coated pellets of erythromycin base for oral administration. Each ERYC capsule contains 250 mg of erythromycin base. Also contains: lactose NF, povidone USP, FD&C Yellow #6 and other ingredients. The capsule shell contai. |
| Active Ingredient | Benzoyl peroxide; erythromycin |
| Dosage Form | Gel |
| Route | Topical |
| Strength | 5%; 3% |
| Market Status | Prescription |
| Company | Valeant Luxembourg |
| 4 of 24 | |
|---|---|
| Drug Name | C-solve-2 |
| Active Ingredient | Erythromycin |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Fougera Pharms |
| 5 of 24 | |
|---|---|
| Drug Name | Eryc |
| Active Ingredient | Erythromycin |
| Dosage Form | Capsule, delayed rel pellets |
| Route | Oral |
| Strength | 250mg |
| Market Status | Prescription |
| Company | Mayne Pharma |
| 6 of 24 | |
|---|---|
| Drug Name | Erygel |
| PubMed Health | Erythromycin (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | ERYGEL Topical Gel USP, 2% contains erythromycin (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl--L-ribo-hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6,-trid... |
| Active Ingredient | Erythromycin |
| Dosage Form | Gel |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Delcor Asset |
| 7 of 24 | |
|---|---|
| Drug Name | Ery-tab |
| PubMed Health | Erythromycin |
| Drug Classes | Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic |
| Drug Label | ERY-TAB (erythromycin delayed-release tablets) is an antibacterial product containing erythromycin base in a specially enteric-coated tablet to protect it from the inactivating effects of gastric acidity and to permit efficient absorption of the anti... |
| Active Ingredient | Erythromycin |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | 250mg; 333mg; 500mg |
| Market Status | Prescription |
| Company | Arbor Pharms |
| 8 of 24 | |
|---|---|
| Drug Name | Erythra-derm |
| Drug Label | Erythromycin is an antibiotic produced from a strain of Streptomyces erythraeus. It is basic and readily forms salts with acids.Chemically, erythromycin is (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-0-methyl-... |
| Active Ingredient | Erythromycin |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Paddock |
| 9 of 24 | |
|---|---|
| Drug Name | Erythrocin |
| PubMed Health | Erythromycin/Benzoyl Peroxide (On the skin) |
| Drug Classes | Antiacne |
| Active Ingredient | Erythromycin lactobionate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Hospira |
| 10 of 24 | |
|---|---|
| Drug Name | Erythrocin stearate |
| Active Ingredient | Erythromycin stearate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 250mg base |
| Market Status | Prescription |
| Company | Arbor Pharms |
| 11 of 24 | |
|---|---|
| Drug Name | Erythromycin |
| Drug Label | ERY-TAB (erythromycin delayed-release tablets) is an antibacterial product containing erythromycin base in a specially enteric-coated tablet to protect it from the inactivating effects of gastric acidity and to permit efficient absorption of the anti... |
| Active Ingredient | Erythromycin |
| Dosage Form | Gel; Swab; Capsule, delayed rel pellets; Ointment; Tablet; Solution |
| Route | Topical; Ophthalmic; Oral |
| Strength | 0.5%; 250mg; 2%; 500mg |
| Market Status | Prescription |
| Company | Arbor Pharms; Wockhardt; Fougera Pharms; Perrigo Co Tennessee; Versapharm; Bausch And Lomb; Perrigo; Perrigo New York; Akorn |
| 12 of 24 | |
|---|---|
| Drug Name | Erythro-statin |
| Active Ingredient | Erythromycin |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Hi Tech Pharma |
| 13 of 24 | |
|---|---|
| Drug Name | Akne-mycin |
| Active Ingredient | Erythromycin |
| Dosage Form | Ointment |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Dow Pharm |
| 14 of 24 | |
|---|---|
| Drug Name | Benzamycin |
| Active Ingredient | Benzoyl peroxide; erythromycin |
| Dosage Form | Gel |
| Route | Topical |
| Strength | 5%; 3% |
| Market Status | Prescription |
| Company | Valeant Intl |
| 15 of 24 | |
|---|---|
| Drug Name | Benzamycin pak |
| Drug Label | ERYC capsules contain enteric-coated pellets of erythromycin base for oral administration. Each ERYC capsule contains 250 mg of erythromycin base. Also contains: lactose NF, povidone USP, FD&C Yellow #6 and other ingredients. The capsule shell contai. |
| Active Ingredient | Benzoyl peroxide; erythromycin |
| Dosage Form | Gel |
| Route | Topical |
| Strength | 5%; 3% |
| Market Status | Prescription |
| Company | Valeant Luxembourg |
| 16 of 24 | |
|---|---|
| Drug Name | C-solve-2 |
| Active Ingredient | Erythromycin |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Fougera Pharms |
| 17 of 24 | |
|---|---|
| Drug Name | Eryc |
| Active Ingredient | Erythromycin |
| Dosage Form | Capsule, delayed rel pellets |
| Route | Oral |
| Strength | 250mg |
| Market Status | Prescription |
| Company | Mayne Pharma |
| 18 of 24 | |
|---|---|
| Drug Name | Erygel |
| PubMed Health | Erythromycin (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | ERYGEL Topical Gel USP, 2% contains erythromycin (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl--L-ribo-hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6,-trid... |
| Active Ingredient | Erythromycin |
| Dosage Form | Gel |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Delcor Asset |
| 19 of 24 | |
|---|---|
| Drug Name | Ery-tab |
| PubMed Health | Erythromycin |
| Drug Classes | Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic |
| Drug Label | ERY-TAB (erythromycin delayed-release tablets) is an antibacterial product containing erythromycin base in a specially enteric-coated tablet to protect it from the inactivating effects of gastric acidity and to permit efficient absorption of the anti... |
| Active Ingredient | Erythromycin |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | 250mg; 333mg; 500mg |
| Market Status | Prescription |
| Company | Arbor Pharms |
| 20 of 24 | |
|---|---|
| Drug Name | Erythra-derm |
| Drug Label | Erythromycin is an antibiotic produced from a strain of Streptomyces erythraeus. It is basic and readily forms salts with acids.Chemically, erythromycin is (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-0-methyl-... |
| Active Ingredient | Erythromycin |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Paddock |
| 21 of 24 | |
|---|---|
| Drug Name | Erythrocin |
| PubMed Health | Erythromycin/Benzoyl Peroxide (On the skin) |
| Drug Classes | Antiacne |
| Active Ingredient | Erythromycin lactobionate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Hospira |
| 22 of 24 | |
|---|---|
| Drug Name | Erythrocin stearate |
| Active Ingredient | Erythromycin stearate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 250mg base |
| Market Status | Prescription |
| Company | Arbor Pharms |
| 23 of 24 | |
|---|---|
| Drug Name | Erythromycin |
| Drug Label | ERY-TAB (erythromycin delayed-release tablets) is an antibacterial product containing erythromycin base in a specially enteric-coated tablet to protect it from the inactivating effects of gastric acidity and to permit efficient absorption of the anti... |
| Active Ingredient | Erythromycin |
| Dosage Form | Gel; Swab; Capsule, delayed rel pellets; Ointment; Tablet; Solution |
| Route | Topical; Ophthalmic; Oral |
| Strength | 0.5%; 250mg; 2%; 500mg |
| Market Status | Prescription |
| Company | Arbor Pharms; Wockhardt; Fougera Pharms; Perrigo Co Tennessee; Versapharm; Bausch And Lomb; Perrigo; Perrigo New York; Akorn |
| 24 of 24 | |
|---|---|
| Drug Name | Erythro-statin |
| Active Ingredient | Erythromycin |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Hi Tech Pharma |
Antibiotics, Macrolide; Gastrointestinal Agents; Protein Synthesis Inhibitors
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
MEDICATION (VET): In veterinary medicine, /erythromycin/ is used the treatment of clinical and subclinical mastitis in lactating cows, for the treatment of infectious diseases due to erythromycin-sensitive bacteria (cattle, sheep, swine, poultry) and for the treatment of chronic respiratory diseases due to mycoplasma in poultry.
Erythromycin is used as an alternative agent in the treatment of anthrax. Parenteral penicillins generally have been considered the drugs of choice for the treatment of naturally occurring or endemic anthrax caused by susceptible strains of Bacillus anthracis, including clinically apparent GI, inhalational, or meningeal anthrax and anthrax septicemia, although IV ciprofloxacin or IV doxycycline also are recommended. Erythromycin is suggested as an alternative to penicillin G for the treatment of naturally occurring or endemic anthrax in patients hypersensitive to penicillins. ./NOT included in US product label/
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 228
Erythromycin is used topically in the treatment of acne vulgaris. Therapy of acne vulgaris must be individualized and frequently modified depending on the types of acne lesions which predominate and the response to therapy. Topical anti-infectives, including erythromycin, are generally effective in the treatment of mild to moderate inflammatory acne. However, use of topical anti-infectives as monotherapy may lead to bacterial resistance; this resistance is associated with decreased clinical efficacy. Topical erythromycin is particularly useful when used with benzoyl peroxide or topical retinoids. Results of clinical studies indicate that combination therapy results in a reduction in total lesion counts of 50 to 70%. /Included in US product label/
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 3511
For more Therapeutic Uses (Complete) data for Erythromycin (23 total), please visit the HSDB record page.
Some commercially available formulations of erythromycin lactobionate powder for injection contain benzyl alcohol as a preservative. Although a causal relationship has not been established, administration of injections preserved with benzyl alcohol has been associated with toxicity in neonates. Toxicity appears to have resulted from administration of large amounts (i.e., about 100-400 mg/kg daily) of benzyl alcohol in these neonates. Although use of drugs preserved with benzyl alcohol should be avoided in neonates whenever possible, the American Academy of Pediatrics states that the presence of small amounts of the preservative in a commercially available injection should not proscribe its use when indicated in neonates. /Erythromycin lactobionate/
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 240
In several neonates with infections caused by Ureaplasma urealyticum who received IV administration of erythromycin lactobionate, adverse cardiac effects (e.g., bradycardia, hypotension, cardiac arrest, arrhythmias) requiring cardiopulmonary resuscitation have been reported. Some clinicians state that these adverse effects may depend on serum concentration and/or infusion rate of the drug. It has been suggested that prolonged IV infusion of erythromycin lactobionate (e.g., over 60 minutes) may reduce such adverse cardiac effects. However, it has been suggested that certain individuals may be at increased risk of developing erythromycin-induced adverse cardiac effects and that decreasing the rate of IV infusion may decrease but not eliminate the risk of such effects. Further study is needed to determine the pharmacokinetics and safety of erythromycin lactobionate in neonates. /Erythromycin lactobionate/
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 240
Maternal Medication usually Compatible with Breast-Feeding: Erythromycin: Reported Sign or Symptom in Infant or Effect on Lactation: None. /From Table 6/
Report of the American Academy of Pediatrics Committee on Drugs in Pediatrics 93 (1): 140 (1994)
POTENTIAL ADVERSE EFFECTS ON FETUS: None known. POTENTIAL SIDE EFFECTS ON BREAST-FED INFANT: None known, although theoretically could cause diarrhea in infant. COMMENTS: Crosses placenta in high doses to fetal level 24% of maternal; breast milk may exceed maternal serum concentration. FDA Category: B (B = Studies in laboratory animals have not demonstrated a fetal risk, but there are no controlled studies in pregnant women; or animal studies have shown an adverse effect (other than a decrease in fertility), but controlled studies in pregnant women have not demonstrated a risk to the fetus in the first trimester and there is no evidence of a risk in later trimesters.) /From Table II/
PMID:2195076 Stockton DL and AS Paller; J Am Acad Dermatol 23 (1): 87-103 (1990)
For more Drug Warnings (Complete) data for Erythromycin (17 total), please visit the HSDB record page.
Erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacteria. The indications for erythromycin have been summarized by body system below: **Respiratory infections** Mild to moderate upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with appropriate doses of sulfonamides) can be treated with erythromycin. Mild to moderate lower-respiratory tract infections due to susceptible strains of Streptococcus pneumoniae or Streptococcus pyogenes may also be treated. Erythromycin treats listeriosis caused by Listeria monocytogenes may also be treated with erythromycin. Erythromycin is indicated to treat pertussis (whooping cough) caused by Bordetella pertussis. It is effective in eliminating the causative organism from the nasopharynx of infected individuals, rendering them noninfectious. Clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacteria. Respiratory tract infections due to Mycoplasma pneumoniae may also be treated with erythromycin. Despite the fact that no controlled clinical efficacy studies have been conducted to this date, in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in Legionnaires Disease. Finally, erythromycin is indicated to treat diphtheria and other infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status and to eradicate the organism in existing carriers. In addition to the prevention of diphtheria, erythromycin can be used to prevent rheumatic fever in penicillin intolerant patients. **Skin infections** Mild to moderate skin or skin structure infections caused by Streptococcus pyogenes or Staphylococcus aureus may be treated with erythromycin, however, resistant staphylococcal organisms may emerge. Erythromycin can also be used to treat erythrasma, an infectious condition caused by Corynebacterium minutissimum. **Gastrointestinal infections** Intestinal amebiasis caused by Entamoeba histolytica can be treated with oral erythromycin. Extraenteric amebiasis warrants treatment with other antimicrobial drugs. **Genital infections/STIs** Erythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by N. gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillin. Syphilis, caused by Treponema pallidum, can be treated with erythromycin. It serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity. Erythromycin can also be used in the primary stage of primary syphilis. Another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy. It is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal, urethral and endocervical infections in adults caused by Chlamydia trachomatis. Erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered. Finally, erythromycin is indicated to treat nongonococcal urethritis due to Ureaplasma urealyticum.
Macrolides, such as erythromycin, stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections. Erythromycin does not exert effects on nucleic acid synthesis. This drug has been shown to be active against most strains of the following microorganisms, effectively treating both in vitro and clinical infections. Despite this, it is important to perform bacterial susceptibility testing before administering this antibiotic, as resistance is a common issue that may affect treatment. **A note on antimicrobial resistance, pseudomembranous colitis, and hepatotoxicity** Many strains of Haemophilus influenzae are resistant to erythromycin alone but are found to be susceptible to erythromycin and sulfonamides used in combination. It is important to note that Staphylococci that are resistant to erythromycin may emerge during erythromycin and/or sulfonamide therapy. Pseudomembranous colitis has been reported with most antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, the physician should consider this diagnosis in patients with diarrhea after the administration of antibacterial agents. Erythromycin can cause hepatic dysfunction, cholestatic jaundice, and abnormal liver transaminases, particularly when erythromycin estolate is administered.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Gastrointestinal Agents
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
D10AF02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
D - Dermatologicals
D10 - Anti-acne preparations
D10A - Anti-acne preparations for topical use
D10AF - Antiinfectives for treatment of acne
D10AF02 - Erythromycin
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01F - Macrolides, lincosamides and streptogramins
J01FA - Macrolides
J01FA01 - Erythromycin
S - Sensory organs
S01 - Ophthalmologicals
S01A - Antiinfectives
S01AA - Antibiotics
S01AA17 - Erythromycin
Absorption
Orally administered erythromycin is readily absorbed. Food intake does not appear to exert effects on serum concentrations of erythromycin. Some interindividual variation exists in terms of erythromycin absorption, which may impact absorption to varying degrees. The Cmax of erythromycin is 1.8 mcg/L and the Tmax is 1.2 hours. The serum AUC of erythromycin after the administration of a 500mg oral dose was 7.33.9 mg.h/l in one pharmacokinetic study. Erythromycin is well known for a bioavailability that is variable (18-45%) after oral administration and its susceptibility to broken down under acidic conditions.
Route of Elimination
In patients with normal liver function, erythromycin concentrates in the liver and is then excreted in the bile.Under 5% of the orally administered dose of erythromycin is found excreted in the urine. A high percentage of absorbed erythromycin is not accounted for, but is likely metabolized.
Volume of Distribution
Erythromycin is found in most body fluids and accumulates in leucocytes and inflammatory liquid. Spinal fluid concentrations of erythromycin are low, however, the diffusion of erythromycin through the blood-brain barrier increases in meningitis, likely due to the presence of inflamed tissues which are easily penetrated. Erythromycin crosses the placenta.
Clearance
The clearance of erythromycin in healthy subjects was 0.53 0.13 l/h/kg after a 125mg intravenous dose. In a clinical study of healthy patients and patients with liver cirrhosis, clearance of erythromycin was significantly reduced in those with severe liver cirrhosis. The clearance in cirrhotic patients was 42.2 10.1 l h1 versus 113.2 44.2 l h-1 in healthy patients.
Absorption of orally administered erythromycins occurs mainly in the duodenum. The bioavailability of the drugs is variable and depends on several factors including the particular erythromycin derivative, the formulation of the dosage form administered, acid stability of the derivative, presence of food in the GI tract, and gastric emptying time.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 234
Erythromycin is rather slowly absorbed after oral administration. peak serum concentrations ranged from 0.1 to 4.8 ug/mL according to the form and the coating of erythromycin administered. The oral absorption is less that 50% and erythromycin is degraded by gastric acid. It is absorbed in the small intestine (mainly in duodenum for humans) as erythromycin base.
Erythromycin diffuses readily into intracellular fluids, achieving antibacterial activity in essentially all sites except the brain and CSF. Erythromycin penetrates into prostatic fluid, achieving concentrations approximately 40% of those in plasma. Concentrations in middle ear exudate reach only 50% of serum concentrations and thus may be inadequate for the treatment of otitis media caused by H. influenzae. Protein binding is approximately 70% to 80% for erythromycin base and even higher, 96%, for the estolate. Erythromycin traverses the placenta, and drug concentrations in fetal plasma are about 5% to 20% of those in the maternal circulation. Concentrations in breast milk are 50% of those in serum.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006., p. 1184
In an in vitro model using human skin, erythromycin was absorbed into the stratum corneum following topical application of 10-20 mg of the drug in a vehicle containing dimethylacetamide and 95% alcohol. The drug does not appear to be absorbed systemically following twice daily application of a 2% solution of the drug in a vehicle containing 77% alcohol and polyethylene glycol and acetone. It is not known if erythromycin is absorbed from intact or denuded skin, wounds, or mucous membranes following topical application of an ointment containing the drug.
American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 3512
For more Absorption, Distribution and Excretion (Complete) data for Erythromycin (13 total), please visit the HSDB record page.
Hepatic first-pass metabolism contributes significantly to erythromycin metabolism after an oral dose. Erythromycin is partially metabolized by CYP3A4 enzyme to N-desmethylerythromycin. Erythromycin is also hydrolyzed to _anhydro_ forms (anhydroerythromycin [AHE] and other metabolites), and this process is promoted by acidic conditions. AHE is inactive against microbes but inhibits hepatic drug oxidation and is therefore considered to be an important contributor to erythromycin drug-drug interactions.
Twenty hours after an oral administration of 10 mg erythromycin to rats, about 37-43% of the administered radioactivity was recovered in the intestinal tract plus feces, 27.2 to 36.1% in the urine, 21-29% in the expired air. It was rapidly metabolized in the liver, mainly through demethylation process, and excreted in the bile as des-N-methyl-erythromycin, the major metabolite present only in the bile and in the intestinal contents of rats. The isotropic methyl group was eliminated in the expired air as CO2.
The elimination half-life of oral erythromycin was 3.5 hours according to one study and ranged between 2.4-3.1 hours in another study. Repetitive dosing of erythromycin leads to increased elimination half-life.
... The serum elimination half-life of erythromycin is approximately 1.6 hours.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006., p. 1184
The serum half-life in normal subjects is 2 hours and in anuric subjects, 4-6 hours.
Ellenhorn, M.J. and D.G. Barceloux. Medical Toxicology - Diagnosis and Treatment of Human Poisoning. New York, NY: Elsevier Science Publishing Co., Inc. 1988., p. 360
In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins. Erythromycin acts by inhibition of protein synthesis by binding to the 23S ribosomal RNA molecule in the 50S subunit of ribosomes in susceptible bacterial organisms. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit. This results in the control of various bacterial infections. The strong affinity of macrolides, including erythromycin, for bacterial ribosomes, supports their broadspectrum antibacterial activities.
Macrolide antibiotics are bacteriostatic agents that inhibit protein synthesis by binding reversibly to 50S ribosomal subunits of sensitive microorganisms, at or very near the site that binds chloramphenicol. Erythromycin does not inhibit peptide bond formation per se, but rather inhibits the translocation step wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl donor site. Gram-positive bacteria accumulate about 100 times more erythromycin than do gram-negative bacteria. Cells are considerably more permeable to the un-ionized form of the drug, which probably explains the increased antimicrobial activity at alkaline pH.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006., p. 1183
... /Erythromycin/ inhibits the growth of susceptible organisms (principally Propionibacterium acnes) on the surface of the skin and reduces the concn of free fatty acids in sebum ... The reduction in free fatty acids in sebum may be an indirect result of the inhibition of lipase-producing organisms which convert triglycerides into free fatty acids or may be a direct result of interference with lipase production in these organisms. /In acne treatment regimens/
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 95. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1995 (Plus Supplements 1995)., p. 2378
Although stromal-derived factor-1 (SDF-1) via its cognate receptor CXCR4 is assumed to play a critical role in migration of endothelial cells during new vessel formation after tissue injury, CXCR4 expression on endothelial cells is strictly regulated. Erythromycin (EM), a 14-membered ring macrolide, has an anti-inflammatory effect that may account for its clinical benefit in the treatment of chronic inflammatory diseases. However, the effects of EM on endothelial cells and especially their expression of CXCR4 have not been fully evaluated. In this study, we demonstrated that EM markedly induced CXCR4 surface expression on microvascular endothelial cells in vitro and lung capillary endothelial cells in vivo. This ability to induce CXCR4 surface expression on endothelial cells was restricted to 14-membered ring macrolides and was not observed in other antibiotics including a 16-membered ring macrolide, josamycin. Furthermore, this EM-induced expression of CXCR4 on endothelial cells was functionally significant as demonstrated by chemotaxis assays in vitro. These findings suggest that EM-induced CXCR4 surface expression on endothelial cells may promote migration of CXCR4-expressing endothelial cells into sites of tissue injury, which may be associated with the known anti-inflammatory activity of this macrolide.
PMID:19502290 Takagi Y et al; Am J Physiol Lung Cell Mol Physiol 297 (3): L420-31 (2009).
API SUPPLIERS
Century has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.
Date of Issue : 2022-11-02
Valid Till : 2024-12-16
Written Confirmation Number : WC-0293
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13197
Submission : 1998-04-30
Status : Active
Type : II
Certificate Number : R1-CEP 1997-001 - Rev 08
Issue Date : 2023-05-23
Type : Chemical
Substance Number : 179
Status : Valid
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.
Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13409
Submission : 1998-09-01
Status : Active
Type : II
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-05-09
Pay. Date : 2013-09-25
DMF Number : 27155
Submission : 2015-11-10
Status : Active
Type : II
Certificate Number : R1-CEP 2016-267 - Rev 00
Issue Date : 2022-03-14
Type : Chemical
Substance Number : 179
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-02
Pay. Date : 2014-09-30
DMF Number : 19444
Submission : 2006-03-20
Status : Active
Type : II
Certificate Number : R1-CEP 2007-153 - Rev 02
Issue Date : 2017-01-20
Type : Chemical
Substance Number : 179
Status : Valid
Registration Number : 231MF10067
Registrant's Address : No. 62 Binjiang Road, Yidu, Hubei Province, P. R. China
Initial Date of Registration : 2019-03-11
Latest Date of Registration :
NDC Package Code : 43781-2103
Start Marketing Date : 2010-09-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12201
Submission : 1996-11-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 633
Submission : 1963-08-05
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 730
Submission : 1963-11-07
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - GEL;TOPICAL - 5%;3%
USFDA APPLICATION NUMBER - 50557
DOSAGE - TABLET, COATED PARTICLES;ORAL - 333M...DOSAGE - TABLET, COATED PARTICLES;ORAL - 333MG
USFDA APPLICATION NUMBER - 50611
DOSAGE - TABLET, COATED PARTICLES;ORAL - 500M...DOSAGE - TABLET, COATED PARTICLES;ORAL - 500MG
USFDA APPLICATION NUMBER - 50611
DOSAGE - GEL;TOPICAL - 2%
USFDA APPLICATION NUMBER - 50617
DOSAGE - GEL;TOPICAL - 5%;3%
USFDA APPLICATION NUMBER - 50769
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seqens
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Fillers, Diluents & Binders
Controlled & Modified Release
Disintegrants & Superdisintegrants
Thickeners and Stabilizers
Direct Compression
Solubilizers
Granulation
Topical
Lubricants & Glidants
Co-Processed Excipients
Film Formers & Plasticizers
Emulsifying Agents
Empty Capsules
Chewable & Orodispersible Aids
Parenteral
Vegetarian Capsules
API Stability Enhancers
Taste Masking
Coloring Agents
Rheology Modifiers
Surfactant & Foaming Agents
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
A Erythromycin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Erythromycin, including repackagers and relabelers. The FDA regulates Erythromycin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Erythromycin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Erythromycin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Erythromycin supplier is an individual or a company that provides Erythromycin active pharmaceutical ingredient (API) or Erythromycin finished formulations upon request. The Erythromycin suppliers may include Erythromycin API manufacturers, exporters, distributors and traders.
click here to find a list of Erythromycin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Erythromycin DMF (Drug Master File) is a document detailing the whole manufacturing process of Erythromycin active pharmaceutical ingredient (API) in detail. Different forms of Erythromycin DMFs exist exist since differing nations have different regulations, such as Erythromycin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Erythromycin DMF submitted to regulatory agencies in the US is known as a USDMF. Erythromycin USDMF includes data on Erythromycin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Erythromycin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Erythromycin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Erythromycin Drug Master File in Japan (Erythromycin JDMF) empowers Erythromycin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Erythromycin JDMF during the approval evaluation for pharmaceutical products. At the time of Erythromycin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Erythromycin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Erythromycin Drug Master File in Korea (Erythromycin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Erythromycin. The MFDS reviews the Erythromycin KDMF as part of the drug registration process and uses the information provided in the Erythromycin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Erythromycin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Erythromycin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Erythromycin suppliers with KDMF on PharmaCompass.
A Erythromycin CEP of the European Pharmacopoeia monograph is often referred to as a Erythromycin Certificate of Suitability (COS). The purpose of a Erythromycin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Erythromycin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Erythromycin to their clients by showing that a Erythromycin CEP has been issued for it. The manufacturer submits a Erythromycin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Erythromycin CEP holder for the record. Additionally, the data presented in the Erythromycin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Erythromycin DMF.
A Erythromycin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Erythromycin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Erythromycin suppliers with CEP (COS) on PharmaCompass.
A Erythromycin written confirmation (Erythromycin WC) is an official document issued by a regulatory agency to a Erythromycin manufacturer, verifying that the manufacturing facility of a Erythromycin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Erythromycin APIs or Erythromycin finished pharmaceutical products to another nation, regulatory agencies frequently require a Erythromycin WC (written confirmation) as part of the regulatory process.
click here to find a list of Erythromycin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Erythromycin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Erythromycin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Erythromycin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Erythromycin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Erythromycin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Erythromycin suppliers with NDC on PharmaCompass.
Erythromycin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Erythromycin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Erythromycin GMP manufacturer or Erythromycin GMP API supplier for your needs.
A Erythromycin CoA (Certificate of Analysis) is a formal document that attests to Erythromycin's compliance with Erythromycin specifications and serves as a tool for batch-level quality control.
Erythromycin CoA mostly includes findings from lab analyses of a specific batch. For each Erythromycin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Erythromycin may be tested according to a variety of international standards, such as European Pharmacopoeia (Erythromycin EP), Erythromycin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Erythromycin USP).
LOOKING FOR A SUPPLIER?
